Skip to content

Market Spectator

Business
Domestic
Economy
Politics
Top News
Newsletters

Search for:

Home
2024
May
6
People with two copies of a risk gene have genetic form of Alzheimer’s, scientists say
FILE PHOTO: Handout image shows Alzheimer’s drug LEQEMBI

FILE PHOTO: Handout image shows Alzheimer’s drug LEQEMBI

FILE PHOTO: The Alzheimer’s drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai/Handout via REUTERS/File Photo

Post navigation

Previous: People with two copies of a risk gene have genetic form of Alzheimer’s, scientists say

Live Market Pulse

The charting technology is provided by TradingView. Learn how to use theTradingView Stock Screener.

Search

Categories

Business
Domestic
Economy
Politics
Top News
Uncategorized

Recent Posts

European drinks group skid after US surgeon general calls for cancer warnings
AI a productivity boost to banks but making money from it is a challenge
Adobe forecasts fiscal 2025 revenue below estimates on slower subscription spending
Microsoft expects $800 million impairment charge in Q2 2025 over General Motors’ Cruise exit
Stunning rally in Big Tech drives Nasdaq to 20,000

You may have missed

2025-01-03T141432Z_1_LYNXMPEL020G8_RTROPTP_4_PERNOD-RICARD-INDIA-RAJASTHAN

Business

European drinks group skid after US surgeon general calls for cancer warnings

Market Spectator January 3, 2025

2024-12-11T214504Z_1_LYNXMPEKBA10D_RTROPTP_4_REUTERS-NEXT-GOLDMAN-SACHS-CEO

Business

AI a productivity boost to banks but making money from it is a challenge

Market Spectator December 11, 2024

2024-12-11T212535Z_1_LYNXMPEKBA102_RTROPTP_4_ADOBE-RESULTS

Business

Adobe forecasts fiscal 2025 revenue below estimates on slower subscription spending

Market Spectator December 11, 2024

2024-12-11T213952Z_1_LYNXMPEKBA109_RTROPTP_4_TECH-ANTIRUST-MICROSOFT

Business

Microsoft expects $800 million impairment charge in Q2 2025 over General Motors’ Cruise exit

Market Spectator December 11, 2024

Home
Terms of Service
Privacy Policy
Disclaimer
Contact Us

Copyright 2025 © All rights reserved | Market Spectator | marketspectator.com